|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADNP |
Gene summary for ADNP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADNP | Gene ID | 23394 |
| Gene name | activity dependent neuroprotector homeobox | |
| Gene Alias | ADNP1 | |
| Cytomap | 20q13.13 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9H2P0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23394 | ADNP | CA_HPV_3 | Human | Cervix | CC | 4.59e-02 | 1.04e-01 | 0.0414 |
| 23394 | ADNP | CCI_1 | Human | Cervix | CC | 3.01e-04 | 6.21e-01 | 0.528 |
| 23394 | ADNP | CCI_2 | Human | Cervix | CC | 9.58e-11 | 8.44e-01 | 0.5249 |
| 23394 | ADNP | CCI_3 | Human | Cervix | CC | 1.70e-16 | 9.09e-01 | 0.516 |
| 23394 | ADNP | T3 | Human | Cervix | CC | 2.96e-04 | 1.44e-01 | 0.1389 |
| 23394 | ADNP | HTA11_3410_2000001011 | Human | Colorectum | AD | 9.66e-08 | -5.06e-01 | 0.0155 |
| 23394 | ADNP | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.01e-02 | -5.70e-01 | -0.2061 |
| 23394 | ADNP | F007 | Human | Colorectum | FAP | 8.30e-03 | 8.30e-02 | 0.1176 |
| 23394 | ADNP | A001-C-207 | Human | Colorectum | FAP | 2.66e-03 | -9.62e-02 | 0.1278 |
| 23394 | ADNP | A015-C-203 | Human | Colorectum | FAP | 5.30e-29 | -3.39e-01 | -0.1294 |
| 23394 | ADNP | A015-C-204 | Human | Colorectum | FAP | 3.73e-05 | -2.21e-01 | -0.0228 |
| 23394 | ADNP | A014-C-040 | Human | Colorectum | FAP | 1.37e-04 | -1.58e-01 | -0.1184 |
| 23394 | ADNP | A002-C-201 | Human | Colorectum | FAP | 3.08e-16 | -3.08e-01 | 0.0324 |
| 23394 | ADNP | A001-C-119 | Human | Colorectum | FAP | 7.37e-08 | -2.86e-01 | -0.1557 |
| 23394 | ADNP | A001-C-108 | Human | Colorectum | FAP | 6.00e-11 | -1.44e-01 | -0.0272 |
| 23394 | ADNP | A002-C-205 | Human | Colorectum | FAP | 1.02e-24 | -3.15e-01 | -0.1236 |
| 23394 | ADNP | A001-C-104 | Human | Colorectum | FAP | 2.73e-02 | -7.39e-02 | 0.0184 |
| 23394 | ADNP | A015-C-005 | Human | Colorectum | FAP | 1.03e-03 | -1.57e-01 | -0.0336 |
| 23394 | ADNP | A015-C-006 | Human | Colorectum | FAP | 8.29e-17 | -2.62e-01 | -0.0994 |
| 23394 | ADNP | A015-C-106 | Human | Colorectum | FAP | 3.51e-10 | -2.48e-01 | -0.0511 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
| GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
| GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
| GO:005109810 | Cervix | CC | regulation of binding | 80/2311 | 363/18723 | 1.32e-07 | 6.42e-06 | 80 |
| GO:00316689 | Cervix | CC | cellular response to extracellular stimulus | 59/2311 | 246/18723 | 3.03e-07 | 1.24e-05 | 59 |
| GO:00343298 | Cervix | CC | cell junction assembly | 88/2311 | 420/18723 | 3.42e-07 | 1.38e-05 | 88 |
| GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
| GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
| GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
| GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
| GO:00160498 | Cervix | CC | cell growth | 92/2311 | 482/18723 | 1.16e-05 | 2.49e-04 | 92 |
| GO:00325359 | Cervix | CC | regulation of cellular component size | 76/2311 | 383/18723 | 1.66e-05 | 3.21e-04 | 76 |
| GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
| GO:000974310 | Cervix | CC | response to carbohydrate | 53/2311 | 253/18723 | 7.02e-05 | 9.85e-04 | 53 |
| GO:007099710 | Cervix | CC | neuron death | 70/2311 | 361/18723 | 7.50e-05 | 1.03e-03 | 70 |
| GO:00074097 | Cervix | CC | axonogenesis | 78/2311 | 418/18723 | 1.14e-04 | 1.43e-03 | 78 |
| GO:00459277 | Cervix | CC | positive regulation of growth | 53/2311 | 259/18723 | 1.33e-04 | 1.64e-03 | 53 |
| GO:00015588 | Cervix | CC | regulation of cell growth | 77/2311 | 414/18723 | 1.40e-04 | 1.70e-03 | 77 |
| GO:00433939 | Cervix | CC | regulation of protein binding | 42/2311 | 196/18723 | 2.27e-04 | 2.55e-03 | 42 |
| GO:190121410 | Cervix | CC | regulation of neuron death | 61/2311 | 319/18723 | 3.11e-04 | 3.31e-03 | 61 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ADNP | CD8TEX | Oral cavity | NEOLP | CDC42,HNRNPH1,C1orf56, etc. | 1.10e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADNP | SNV | Missense_Mutation | novel | c.1603N>T | p.His535Tyr | p.H535Y | Q9H2P0 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| ADNP | SNV | Missense_Mutation | c.2618N>G | p.Asp873Gly | p.D873G | Q9H2P0 | protein_coding | tolerated_low_confidence(0.22) | benign(0.175) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ADNP | SNV | Missense_Mutation | c.2200G>A | p.Asp734Asn | p.D734N | Q9H2P0 | protein_coding | tolerated(0.36) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ADNP | SNV | Missense_Mutation | novel | c.1363N>A | p.Leu455Ile | p.L455I | Q9H2P0 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADNP | SNV | Missense_Mutation | novel | c.976N>A | p.His326Asn | p.H326N | Q9H2P0 | protein_coding | tolerated(0.17) | probably_damaging(0.956) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADNP | SNV | Missense_Mutation | novel | c.2521N>C | p.Asp841His | p.D841H | Q9H2P0 | protein_coding | deleterious(0.01) | possibly_damaging(0.536) | TCGA-AN-A0AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADNP | SNV | Missense_Mutation | novel | c.1364T>C | p.Leu455Pro | p.L455P | Q9H2P0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADNP | SNV | Missense_Mutation | c.1041N>A | p.Met347Ile | p.M347I | Q9H2P0 | protein_coding | tolerated(0.49) | benign(0) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| ADNP | SNV | Missense_Mutation | c.3244N>A | p.Asp1082Asn | p.D1082N | Q9H2P0 | protein_coding | deleterious_low_confidence(0.01) | benign(0.173) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| ADNP | SNV | Missense_Mutation | c.3087N>C | p.Lys1029Asn | p.K1029N | Q9H2P0 | protein_coding | tolerated_low_confidence(0.43) | probably_damaging(0.981) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |